Compare Cytokinetics Inc (CYTK) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Open Text Corporation — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Open Text Corporation trades at $23.1 (market cap $5.61B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Open Text Corporation pays a 4.82% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Open Text Corporation for 23 Days on average.
| CYTK | OTEX | |
|---|---|---|
Market Cap | $8.62B | $5.61B |
Volume | 2,594,626 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $87.26 | $39.69 |
52-Week Low | $54.76 | $20.01 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $8.72B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
OpenText (OTEX) trades at $23.14, up 1.89% today, with strong technical momentum indicated by a bullish overall signal. The company demonstrates robust fundamentals with consistent earnings beats, posting Q2 2026 EPS of $1.23 versus $1.02 expected, and maintains healthy profitability with 12.26% net income margin. Recent corporate actions include a $1 billion senior secured notes offering and strategic AI partnerships, signaling growth initiatives.
The stock presents an attractive valuation opportunity with P/E of 9.01 and P/S of 1.1 below sector averages, supported by analyst consensus target of $28.30 implying 22% upside. Key risks include high debt levels at $6.34 billion and competitive pressures in the software sector. Institutional sentiment remains mixed with 42% buy ratings amid ongoing debt management efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
